Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Update on the management of non-muscle invasive bladder cancer.

Literature DB >> 20165581

Update on the management of non-muscle invasive bladder cancer.

Abstract

Non-muscle invasive bladder cancer (NMIBC) is a heterogeneous population of tumours accounting for 80% of bladder cancers. Over the years, the management of this disease has been changing with improvements in results and outcomes. In this review, we focus on the latest updates on the management of NMIBC.

Entities: Disease

Year: 2010 PMID： 20165581 PMCID： PMC2812001 DOI： 10.5489/cuaj.777

Source DB: PubMed Journal: Can Urol Assoc J ISSN： 1911-6470 Impact factor: 1.862

128 in total

Review 1. Bladder cancer: epidemiology, staging and grading, and diagnosis.

Authors: Ziya Kirkali; Theresa Chan; Murugesan Manoharan; Ferran Algaba; Christer Busch; Liang Cheng; Lambertus Kiemeney; Martin Kriegmair; R Montironi; William M Murphy; Isabell A Sesterhenn; Masaaki Tachibana; Jeff Weider
Journal: Urology Date: 2005-12 Impact factor: 2.649

2. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C.

Authors: Marco Racioppi; Angelo Porreca; Nazario Foschi; Giampaolo Delicato; Antonio Destito; Alessandro D'Addessi
Journal: Urol Int Date: 2005 Impact factor: 2.089

3. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer.

Authors: Fadi N Joudi; Brian J Smith; Michael A O'Donnell
Journal: Urol Oncol Date: 2006 Jul-Aug Impact factor: 3.498

4. A re-staging transurethral resection predicts early progression of superficial bladder cancer.

Authors: Harry W Herr; S Machele Donat
Journal: BJU Int Date: 2006-03-23 Impact factor: 5.588

5. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.

Authors: Harry W Herr
Journal: J Urol Date: 2005-12 Impact factor: 7.450

6. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.

Authors: Savino M Di Stasi; Antonella Giannantoni; Arcangelo Giurioli; Marco Valenti; Germano Zampa; Luigi Storti; Francesco Attisani; Andrea De Carolis; Giovanni Capelli; Giuseppe Vespasiani; Robert L Stephen
Journal: Lancet Oncol Date: 2006-01 Impact factor: 41.316

7. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

Authors: Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth
Journal: Eur Urol Date: 2006-01-17 Impact factor: 20.096

8. Cancer statistics, 2007.

Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun
Journal: CA Cancer J Clin Date: 2007 Jan-Feb Impact factor: 508.702

9. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma.

Authors: Ashish M Kamat; Jason R Gee; Colin P N Dinney; H Barton Grossman; David A Swanson; Randall E Millikan; Michelle A Detry; Tracy L Robinson; Louis L Pisters
Journal: J Urol Date: 2006-03 Impact factor: 7.450

10. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.

Authors: Stefan Denzinger; Maximilian Burger; Bernhard Walter; Ruth Knuechel; Wolfgang Roessler; Wolf F Wieland; Thomas Filbeck
Journal: Urology Date: 2007-04 Impact factor: 2.649

35 in total

1. Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.

Authors: Mandy L Y Sin; Kathleen E Mach; Rahul Sinha; Fan Wu; Dharati R Trivedi; Emanuela Altobelli; Kristin C Jensen; Debashis Sahoo; Ying Lu; Joseph C Liao
Journal: Clin Cancer Res Date: 2017-02-13 Impact factor: 12.531

2. Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progression.

Authors: Shugo Yajima; Soichiro Yoshida; Taro Takahara; Yuki Arita; Hiroshi Tanaka; Yuma Waseda; Minato Yokoyama; Junichiro Ishioka; Yoh Matsuoka; Kazutaka Saito; Kazunori Kihara; Yasuhisa Fujii
Journal: Eur Radiol Date: 2019-03-19 Impact factor: 5.315

3. Multimodal 3D cancer-mimicking optical phantom.

Authors: Gennifer T Smith; Kristen L Lurie; Dimitar V Zlatev; Joseph C Liao; Audrey K Ellerbee Bowden
Journal: Biomed Opt Express Date: 2016-01-25 Impact factor: 3.732

4. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with non-muscle invasive bladder cancer? An update and cumulative meta-analysis.

Authors: Jiangang Pan; Mo Liu; Xing Zhou
Journal: Front Med Date: 2014-05-08 Impact factor: 4.592

5. Dual strands of the miR-223 duplex (miR-223-5p and miR-223-3p) inhibit cancer cell aggressiveness: targeted genes are involved in bladder cancer pathogenesis.

Authors: Sho Sugawara; Yasutaka Yamada; Takayuki Arai; Atsushi Okato; Tetsuya Idichi; Mayuko Kato; Keiichi Koshizuka; Tomohiko Ichikawa; Naohiko Seki
Journal: J Hum Genet Date: 2018-03-14 Impact factor: 3.172

6. Monthly intravesical bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute.

Authors: Koo Han Yoo; Tae Joon Lim; Sung-Goo Chang
Journal: Exp Ther Med Date: 2011-12-01 Impact factor: 2.447

7. Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex.

Authors: Scott J Weir; Prasad Dandawate; David Standing; Sangita Bhattacharyya; Prabhu Ramamoorthy; Parthasarathy Rangarajan; Robyn Wood; Amanda E Brinker; Benjamin L Woolbright; Mehmet Tanol; Tammy Ham; William McCulloch; Michael Dalton; Gregory A Reed; Michael J Baltezor; Roy A Jensen; John A Taylor; Shrikant Anant
Journal: Cell Death Dis Date: 2021-05-31 Impact factor: 8.469